(FOLD) Amicus Therapeutics - Ratings and Ratios
Galafold, Pombiliti, Opfolda, Gene Therapy
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 41.1% |
| Value at Risk 5%th | 60.0% |
| Relative Tail Risk | -11.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.99 |
| Alpha | 38.30 |
| CAGR/Max DD | 0.13 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.394 |
| Beta | 0.701 |
| Beta Downside | 0.682 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.16% |
| Mean DD | 26.26% |
| Median DD | 25.03% |
Description: FOLD Amicus Therapeutics November 11, 2025
Amicus Therapeutics, Inc. (NASDAQ: FOLD) is a U.S.-based biotech focused on developing oral and enzyme-replacement therapies for rare genetic disorders, primarily Fabry disease and late-onset Pompe disease.
The company’s commercial portfolio currently includes Galafold, an oral chaperone therapy for Fabry patients with amenable GLA mutations, and the two-component regimen Pombiliti + Opfolda for adult Pompe disease. Galafold is co-developed and co-commercialized with GlaxoSmithKline under a long-term licensing agreement that provides Amicus with upfront, milestone and royalty payments.
Key recent financial metrics (FY 2023): revenue of approximately $120 million, driven largely by Galafold sales; a net loss of about $200 million reflecting continued R&D investment; and cash and marketable securities of roughly $600 million, giving the firm > 18 months of runway at current burn rates.
Sector-level drivers that shape Amicus’s outlook include the U.S. Orphan Drug Act’s 7-year exclusivity and premium pricing environment, a projected CAGR of ~ 12 % for the rare-disease therapeutics market through 2030, and increasing payer acceptance of oral enzyme-stabilizing agents versus intravenous infusions.
For a data-rich, quantitative assessment of Amicus’s valuation relative to peers, you may find the analytics on ValueRay worth a deeper look.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-14.1m TTM) > 0 and > 6% of Revenue (6% = 35.9m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA 5.12pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 66.00% (prev 68.94%; Δ -2.94pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.01 (>3.0%) and CFO 13.0m > Net Income -14.1m (YES >=105%, WARN >=100%) |
| Net Debt (252.3m) to EBITDA (59.3m) ratio: 4.26 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (310.4m) change vs 12m ago 1.88% (target <= -2.0% for YES) |
| Gross Margin 89.46% (prev 89.99%; Δ -0.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 72.33% (prev 62.76%; Δ 9.57pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.11 (EBITDA TTM 59.3m / Interest Expense TTM 46.7m) >= 6 (WARN >= 3) |
Altman Z'' -11.50
| (A) 0.45 = (Total Current Assets 594.1m - Total Current Liabilities 198.9m) / Total Assets 868.8m |
| (B) -3.19 = Retained Earnings (Balance) -2.77b / Total Assets 868.8m |
| warn (B) unusual magnitude: -3.19 — check mapping/units |
| (C) 0.06 = EBIT TTM 51.7m / Avg Total Assets 827.7m |
| (D) -4.30 = Book Value of Equity -2.74b / Total Liabilities 638.4m |
| Total Rating: -11.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 51.80
| 1. Piotroski 2.0pt |
| 2. FCF Yield 0.21% |
| 3. FCF Margin 1.62% |
| 4. Debt/Equity 1.92 |
| 5. Debt/Ebitda 4.26 |
| 6. ROIC - WACC (= -3.56)% |
| 7. RoE -6.84% |
| 8. Rev. Trend 96.51% |
| 9. EPS Trend 85.16% |
What is the price of FOLD shares?
Over the past week, the price has changed by +0.21%, over one month by +44.97%, over three months by +75.00% and over the past year by +53.55%.
Is FOLD a buy, sell or hold?
- Strong Buy: 8
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the FOLD price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.8 | 3.9% |
| Analysts Target Price | 14.8 | 3.9% |
| ValueRay Target Price | 16.1 | 12.6% |
FOLD Fundamental Data Overview January 05, 2026
P/E Forward = 30.3951
P/S = 7.3722
P/B = 19.1549
P/EG = -0.18
Beta = 0.461
Revenue TTM = 598.7m USD
EBIT TTM = 51.7m USD
EBITDA TTM = 59.3m USD
Long Term Debt = 392.0m USD (from longTermDebt, last quarter)
Short Term Debt = 8.66m USD (from shortTermDebt, last quarter)
Debt = 442.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 252.3m USD (from netDebt column, last quarter)
Enterprise Value = 4.59b USD (4.41b + Debt 442.8m - CCE 263.8m)
Interest Coverage Ratio = 1.11 (Ebit TTM 51.7m / Interest Expense TTM 46.7m)
FCF Yield = 0.21% (FCF TTM 9.69m / Enterprise Value 4.59b)
FCF Margin = 1.62% (FCF TTM 9.69m / Revenue TTM 598.7m)
Net Margin = -2.35% (Net Income TTM -14.1m / Revenue TTM 598.7m)
Gross Margin = 89.46% ((Revenue TTM 598.7m - Cost of Revenue TTM 63.1m) / Revenue TTM)
Gross Margin QoQ = 87.38% (prev 90.16%)
Tobins Q-Ratio = 5.29 (Enterprise Value 4.59b / Total Assets 868.8m)
Interest Expense / Debt = 2.64% (Interest Expense 11.7m / Debt 442.8m)
Taxrate = 49.51% (17.0m / 34.3m)
NOPAT = 26.1m (EBIT 51.7m * (1 - 49.51%))
Current Ratio = 2.99 (Total Current Assets 594.1m / Total Current Liabilities 198.9m)
Debt / Equity = 1.92 (Debt 442.8m / totalStockholderEquity, last quarter 230.4m)
Debt / EBITDA = 4.26 (Net Debt 252.3m / EBITDA 59.3m)
Debt / FCF = 26.03 (Net Debt 252.3m / FCF TTM 9.69m)
Total Stockholder Equity = 205.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -1.62% (Net Income -14.1m / Total Assets 868.8m)
RoE = -6.84% (Net Income TTM -14.1m / Total Stockholder Equity 205.6m)
RoCE = 8.65% (EBIT 51.7m / Capital Employed (Equity 205.6m + L.T.Debt 392.0m))
RoIC = 4.37% (NOPAT 26.1m / Invested Capital 596.6m)
WACC = 7.94% (E(4.41b)/V(4.86b) * Re(8.60%) + D(442.8m)/V(4.86b) * Rd(2.64%) * (1-Tc(0.50)))
Discount Rate = 8.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.83%
[DCF Debug] Terminal Value 67.98% ; FCFE base≈9.69m ; Y1≈6.36m ; Y5≈2.91m
Fair Price DCF = 0.17 (DCF Value 52.1m / Shares Outstanding 309.3m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 85.16 | EPS CAGR: 149.9% | SUE: -1.15 | # QB: 0
Revenue Correlation: 96.51 | Revenue CAGR: 21.22% | SUE: 0.66 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.09 | Chg30d=-0.017 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=0.65 | Chg30d=-0.035 | Revisions Net=-1 | Growth EPS=+71.1% | Growth Revenue=+18.4%
Additional Sources for FOLD Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle